Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Koene

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Haematologica|November 27, 2014
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patientsJaap J Zwaginga, Bronno van der Holt, Peter A Te Boekhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
The Lancet. Haematology|March 3, 2022
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trialSabina Kersting, Julie Dubois, Kazem Nasserinejad, et al.
Blood|June 26, 2023
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Claudia A M Stege, Sabina Kersting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.
Haematologica|November 27, 2014
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patientsJaap J Zwaginga, Bronno van der Holt, Peter A Te Boekhorst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2024
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin LymphomaSuzanne I M Neppelenbroek, Yvonne M Geurts, Berthe M P Aleman, et al.
Haematologica|December 1, 2020
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trialMartine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, et al.
ESMO Open|February 13, 2024
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphomaY M Geurts, S I M Neppelenbroek, B M P Aleman, et al.
The Lancet. Haematology|March 3, 2022
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trialSabina Kersting, Julie Dubois, Kazem Nasserinejad, et al.
Blood|June 26, 2023
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Claudia A M Stege, Sabina Kersting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Journal of the National Cancer Institute|March 25, 2026
Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphomaYvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, et al.
Blood Advances|April 18, 2025
Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOPMarcel Nijland, Djamila E Issa, Johanna A A Bult, et al.
Pageof 7